Drugs / HLX12
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03863587 | Jun → Sep 2019 | — | Shanghai Henlius Biotech | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03863587 ↗ |
| Route | Intravenous | “HLX12 are given intravenous infusion 8 mg/kg” NCT03863587 ↗ |